Daniel Schuppmann, LL.M.
Senior Associate
- Intellectual Property
- Life Sciences
- Commercial Agreements
- Technology & Data Protection
Daniel is a Senior Associate at NEUWERK specializing in intellectual property and information technology law, commercial matters and agreements within the life science industry.
His advisory focus is on the licensing and commercialization of IP rights. Additionally, he advises clients on technology and data protection law as well as in the context of M&A transactions, carve-outs and all types of commercial agreements.
Daniel has extensive experience advising biotech, medtech and pharma clients with the protection. He specializes in the protection and licensing of technologies, the negotiation of research collaborations and all questions relating to the development, manufacturing and distribution of pharmaceutical products, biologics, and MedTech solutions.
In 2024, the German Newspaper Handelsblatt recognized Daniel Schuppmann as “One to Watch - Lawyer of the Future” in the fields of Intellectual Property and IT Law.
CV
Daniel studied law at Bucerius Law School in Hamburg and at Singapore Management University in Singapore. He also completed the LL.M. program "International Technology Law" at the Vrije Universiteit in Amsterdam, with a focus on legal issues relating to the use of artificial intelligence in the medical sector.
Daniel completed his legal clerkship at the Hanseatic Higher Regional Court in Hamburg, during which he worked for Hogan Lovells in the practice group "IP, Media & Technology" as well as at a chamber at the Regional Court of Hamburg specialized in intellectual property law. He further worked for the South Korean law firm Kim & Chang in Seoul and NEUWERK in his current areas of practice.
Recent work
The University Hospital of Cologne on a licensing and cooperation agreement with BioNTech for research into new approaches against HIV
A Berlin-based biotechnology company on a licensing and distribution collaboration in the field of severe bacterial infections with a U.S. pharmaceutical company, as well as ongoing advice on all license and distribution cooperation
A leading European pharmaceutical company on manufacturing and distribution issues in connection with an envisaged carve-out and acquisition of a comprehensive product portfolio from a globally operating pharma company
A leading German medical technology and healthcare company in the legal support and assistance with IT outsourcing projects
A Hamburg-based leading developer of software solutions in the field of advanced real-time 3D graphic (e.g. for Olympic Games or the Super Bowl) in providing ongoing legal advice on all IT contracts
A Hamburg-based eHealth specialist service provider for patient monitoring services in intensive care units, in the preparation of all contracts related to the establishment of the central IT systems and for the conclusion of outsourcing and service collaborations with several hospital groups
A leading European protein engineering company on multiple commercial and IP-related agreements, including a global, high-value R&D-collaboration and licensing arrangement
An international chemical group, in the complete data protection reorganization of the group after a carve-out
A German pharmaceutical company on an envisaged divestiture and related license and supply agreement regarding one of its best-selling products to a global pharmaceutical company for the Spanish market
A digital health start-up on all legal matters, particularly regarding questions surrounding clinical trials, digital health applications, data protection, terms of use, distribution, and cooperation agreements
Publications
Datenschutz in klinischen Prüfungen/Studien aus juristischer Sicht, Presentation at the annual meeting of the German Quality Management Association e.V., March 2024
From Lab to Launch: Navigating the Legal Labyrinth of Life Science Startups - How to Transfer Intellectual Property from Academia to the Market and Navigate the Nuances of Founding a Company in Germany, Presentation at the Life Science Start-up Day 2024 (organized by: BioRegioN, Life Science Factory, Ottobock, Sartorius and startup.niedersachsen)
Regulierung von KI durch EU-Gesetzgebung. Was erwartet die Life-Sciences-Industrie durch die geplante KI-Verordnung?, Plattform Life Sciences, 3/2022
Rechtliche Fragen der Kommerzialisierung von KI-Systemen, Plattform Life Sciences, 2/2021
Languages
German
English